Since METTL3 is an independent adverse prognostic factor, we next compared the clinical characteristics of METTL3‐positive and METTL3‐negative primary AML patients and found that METTL3‐positive AML patients were more likely to harbor DNMT3A mutations (p = 0.036) (Table S4). This evidence concerns the gene DNMT3A and acute myeloid leukemia.